Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study

Kenneth W. Baran, Michel Nguyen, George R. McKendall, Costas T. Lambrew, Gary Dykstra, Sebastian T. Palmeri, Raymond J. Gibbons, Steven Borzak, Burton E. Sobel, Steven G. Gourlay, Amy Chen Rundle, C. Michael Gibson, Hal V. Barron

Research output: Contribution to journalArticle

163 Scopus citations

Abstract

Background - Inhibition of leukocyte adhesion can reduce myocardial infarct size in animals. This study was designed to define the safety and efficacy of a recombinant, humanized, monoclonal antibody to the CD18 subunit of the β2 integrin adhesion receptors (rhuMAb CD18), in reducing infarct size in patients treated with a thrombolytic agent. Methods and Results - The Limitation of Myocardial Infarction following Thrombolysis in Acute Myocardial Infarction Study (LIMIT AMI) was a randomized, double-blind, placebo-controlled, multicenter study conducted in 60 centers in the United States and Canada. A total of 394 subjects who presented within 12 hours of symptom onset with ECG findings (ST-segment elevation) consistent with AMI were treated with recombinant tissue plasminogen activator and were also given an intravenous bolus of 0.5 or 2.0 mg/kg rhuMAb CD18 or placebo. Coronary angiography was performed at 90 minutes, 12-lead ECGs were obtained at baseline, 90, and 180 minutes, and resting sestamibi scans were performed at ≥ 120 hours. Adjunctive angioplasty and use of glycoprotein IIb/IIIa antiplatelet agents at the time of angiography were discretionary. There were no treatment effects on coronary blood flow, infarct size, or the rate of ECG ST-segment elevation resolution, despite the expected induction of peripheral leukocytosis. A slight trend toward an increase in bacterial infections was observed with rhuMAb CD18 (P = 0.33). Conclusions - RhuMAb CD18 was well tolerated but not effective in modifying cardiac end points.

Original languageEnglish (US)
Pages (from-to)2778-2783
Number of pages6
JournalCirculation
Volume104
Issue number23
DOIs
StatePublished - Dec 4 2001

Keywords

  • Antibodies
  • Cell adhesion molecules
  • Inflammation
  • Myocardial infarction
  • Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study'. Together they form a unique fingerprint.

  • Cite this

    Baran, K. W., Nguyen, M., McKendall, G. R., Lambrew, C. T., Dykstra, G., Palmeri, S. T., Gibbons, R. J., Borzak, S., Sobel, B. E., Gourlay, S. G., Rundle, A. C., Gibson, C. M., & Barron, H. V. (2001). Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation, 104(23), 2778-2783. https://doi.org/10.1161/hc4801.100236